Liquid Biopsy in the OMICS Era of Tumor Medicine: (OAJBEB) - Lupine Publishers

Liquid Biopsy in the OMICS Era of Tumor Medicine by Yi Jiang and Denong Wang in Open Access Journal of Biomedical Engineering and Biosciences (OAJBEB) in Lupine Publishers

Liquid biopsy uses noninvasive blood test to assess tumor heterogeneity and evolution in real time. It looks for tumor components in the blood circulation, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), to provide tumor-specific information. By detecting multiplex tumor biomarkers, including nucleic acids, proteins, carbohydrates, and other tumor-derived substances, liquid biopsy helps with early tumor diagnosis, tumor evolution monitoring, and prognosis prediction. With the development of high-throughput OMICS tools like carbohydrate microarray and high-speed fiber-optic array scanning technology (FAST scan), it is now practical to identify glycan markers of CTCs and cancer stem cells(CSCs), especially those that are cell-surface exposed and readily accessible for immune recognition and targeting. Potential of this class of biomarkers in tumor sub typing and targeted immunotherapy is yet to be explored.

https://www.lupinepublishers.com/oajbeb/abstracts/OAJBEB.MS.ID.000115.php

https://lupinepublishers.com/biomedical-sciences-journal/fulltext/liquid-biopsy-in-the-oMICS-era%20of-tumor-medicine.ID.000115.php

https://www.lupinepublishers.com/oajbeb/pdf/OAJBEB.MS.ID.000115.pdf